Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions

Show simple item record

dc.contributor.author Rangel, Erika B. [UNIFESP]
dc.date.accessioned 2016-01-24T14:38:10Z
dc.date.available 2016-01-24T14:38:10Z
dc.date.issued 2014-11-01
dc.identifier http://dx.doi.org/10.1517/17425255.2014.964205
dc.identifier.citation Expert Opinion On Drug Metabolism & Toxicology. London: Informa Healthcare, v. 10, n. 11, p. 1585-1605, 2014.
dc.identifier.issn 1742-5255
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/38438
dc.description.abstract Introduction: With further reduction in surgical complications and improvement in immunosuppressive protocols, pancreas transplant offers excellent outcomes for patients with diabetes. However, long-term survival of pancreas allograft is affected not only by rejection but also by immunosuppressive regimen toxicity.Areas covered: This article reviews the existing literature and knowledge of tacrolimus toxicity and focuses on its diabetogenic effect after pancreas transplant. Some clinically relevant drug-drug interactions with glucocorticoids and sirolimus are also highlighted. This review also summarizes the diabetogenic mechanisms of tacrolimus, the alternatives to minimize these effects, and the main differential diagnosis of hyperglycemia after pancreas transplant.Expert opinion: Tacrolimus is a potent calcineurin inhibitor, an important pathway that regulates pancreatic development. Tacrolimus can induce beta-cell apoptosis, decrease insulin exocytosis and reduce insulin gene transcription, which ultimately lead to impaired functional beta-cell mass after pancreas transplant. Furthermore, insulin resistance can exacerbate the diabetogenic effect of tacrolimus due to inhibition of insulin gene transcription and beta-cell proliferation. It is important to critically analyze the results of clinical studies and investigate new immunosuppressive drugs and/or novel drug combinations. It is equally important to comprehend and interpret experimental data. Therefore, minimization of side effects, based on safe approaches, can prolong pancreas allograft survival. en
dc.format.extent 1585-1605
dc.language.iso eng
dc.publisher Informa Healthcare
dc.relation.ispartof Expert Opinion On Drug Metabolism & Toxicology
dc.rights Acesso restrito
dc.subject hyperglycemia en
dc.subject new-onset of diabetes after transplant en
dc.subject pancreas transplant en
dc.subject post-transplant diabetes mellitus en
dc.subject tacrolimus en
dc.title Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions en
dc.type Resenha
dc.rights.license http://informahealthcare.com/userimages/ContentEditor/1255620309227/Copyright_And_Permissions.pdf
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Albert Einstein Hosp
dc.description.affiliation Universidade Federal de São Paulo, Div Nephrol, Transplant Unit, São Paulo, Brazil
dc.description.affiliation Albert Einstein Hosp, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Div Nephrol, Transplant Unit, São Paulo, Brazil
dc.identifier.doi 10.1517/17425255.2014.964205
dc.description.source Web of Science
dc.identifier.wos WOS:000343976500008



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account